Guardant Health, Inc. (GH)

In the past six months, Guardant Health's stock has experienced several notable events, including exceeding analyst estimates in Q2 CY2025, reaching new 12-month and 52-week highs, and receiving reaffirmed "buy" or "outperform" ratings from numerous equities research analysts. Insiders have sold shares worth approximately $17.98 million. Guardant Health announced a strategic partnership with Zephyr AI and received FDA approval for Guardant360 CDx as a companion diagnostic. The company has also presented clinical data at major medical conferences.

Based on the available information, there is no explicit indication of significant demand seasonality for Guardant Health's products and services. The company has reported robust demand across its core oncology and screening businesses, with expectations for sustained oncology volume growth. Demand for cancer diagnostics and screening typically does not exhibit strong seasonal fluctuations.

Guardant Health, Inc. (GH) is a precision oncology company focused on transforming cancer care through blood-based tests, data sets, and AI analytics. The company operates in the Healthcare sector, specifically in the Diagnostics & Research and Biomed/Gene industries, specializing in liquid biopsy technology. Its major products include Guardant360, Guardant Reveal, Shield, LUNAR platform, GuardantOMNI, GuardantINFINITY, GuardantINFORM, and GuardantConnect.

Guardant Health provides its blood and tissue tests and data sets in the United States and internationally. The company has expanded its operations globally, establishing partnerships with cancer centers in Europe and Asia. Guardant360 CDx has received regulatory approval and national reimbursement in Japan.

Guardant Health's brand reputation in the past year appears to be largely positive, driven by scientific advancements and strategic collaborations. The FDA approval of Guardant360 CDx, the partnership with Zephyr AI, presentations at medical conferences, positive analyst ratings, and the stock reaching new 52-week highs all contribute to its reputation. While there was a "sell" rating from Weiss Ratings, the overall sentiment indicates a generally strong brand reputation.

Major institutional owners of Guardant Health, Inc. include Driehaus Capital Management LLC, ARK Investment Management LLC, Invesco Ltd., Vanguard Group, BlackRock, Deep Track Capital, Capital Research and Management Company - Division 3, Baillie Gifford & Co, Cadian Capital Management, Citadel Advisors, Eventide Asset Management, Geode Capital Management, Millennium Management, State Street Corporation, UBS Global Asset Management Americas, and Two Sigma Advisers. Corporate insiders collectively own 6.10% of the stock.